English 中文


To provide high-quality medicines for the children

BEIMEI R&D Center for Pediatric Medicines

Beimei has established a nearly 3,000-square-meter innovation R&D center for pediatric medicines in the International Biomedical Industrial Park of the Futian Free Trade Zone and Shenzhen Bio-Incubator, and established Beimei Research & Development (Shenzhen) Co. Ltd. in August 2022. Our R&D team has nearly 100 R&D personnel, including PhDs, masters, oversea returnees, and core technical talents, accounting for more than half of Beimei's total employees and providing a strong workforce for the Beimei's high-quality development.

And Beimei has established in-depth and extensive cooperation and exchanges on scientific research projects with China Pharmaceutical University and several domestic and oversea professional drug R&D institutions.

Aiming at the pain points of clinical pediatric medication, Beimei has built three major technology platforms with independent intellectual property rights: pediatric sustained-release formulation, oral thin film and topical transdermal gel, and developed a series of high-end products suitable for children, including inhalation, oral suspension, oral solution, oral thin film and other dosage forms. Furthermore, from the perspective of improving the treatment compliance of pediatric medicines, Beimei has developed innovative taste-masking technology, mixed granulation and other formulation process technologies with independent intellectual property rights, which forms a strong R&D capability of state-of-the-art formulation technology for pediatric prescription medicines.

Beimei R&D Technology Platform

Sustained-Release Technology

Sustained-Release Technology for Solid Preparation: SUSCRE Multi-Particulate Sustained-Release System

Technical core points: Based on the physiological characteristics and tolerance of children in different ages, the development of multi-particulate sustained-release preparation is under scientific design in consideration with the onset period of treatment for specific indications, based on the in vivo sustained-release pattern, and achieved through innovative formulation process technology.

Unique sustained-release mechanism: By simulating zero-order release model, pediatric drug administration can quickly reach and maintain a stable therapeutic plasma concentration, that is, by designing a combination of particles with different release rates to construct different release profiles, the immediate-release granules can quickly reach the onset concentration, while the sustained-release granules can be stably released within a set time to maintain the efficacy.

Clinical value focused: According to the physiological and psychological characteristics of each specific age group of children, the drug release technology is customized to achieve the drug release in a specific period and specific area by the designed release profiles, reducing drug doses, and improve the treatment compliance in children.

Taste-masking combined: Our pediatric drugs with two-layer coating realizes the combination of sustained-release technology and pediatric taste-masking to adjust the flavour for specific pediatric populations, enhancing the treatment compliance.

Sustained-Release Oral Suspension Technology: PENNKINETIE System

Technical breakthrough: Breakthrough the difficulty of the liquid system to ensure the sustained and controlled release effect, the sudden release of drugs in the aqueous environment is avoided, achieving the sustained release effect according to the set release rate;

Compound drug release mechanism: The innovative method of combining ion exchange technology and microparticle coating technology is used to form a unique resin microcapsule structure, which eliminates the impact of gastric emptying and prolongs the release time;

Good taste adjustment: The resin microcapsule uses the dual barrier of ionic complex and coating to effectively mask the bitter taste of the active ingredient, supplemented by Beimei's unique taste masking technology, to form a suitable taste for children and improve the medication compliance in pediatric population;

Convenient dosage adjustment: The liquid suspension system, equipped with special dosing devices, is designed to calculate the dosage according to the weight of the child population in kilograms, etc., to achieve accurate dosage adjustment and solve the shortcomings of pediatric clinical medication.

Taste-masking Technology

Taste-masking is one of the main focuses of pediatric drugs to improve medication compliance in pediatric patients, whose R&D direction of this platform covers the use of a variety of pharmaceutical technologies to mask the bitter taste of active ingredients. From the perspective of prescription process, it includes pellet coating and sustained-release technology, ion exchange resin and active ingredient forming ionic bonding complex technology, cyclodextrin hydrophobic cavity and active ingredient forming complex technology, polymer micelles and vesicle technology, etc.; and it covers the addition of sweeteners, flavors and other functional excipients to achieve the effect of taste masking in the formulation. The subjective and objective taste evaluation system of pediatric drugs is also one of the key focuses of the establishment of pediatric drug taste-masking platform.

Taste-masking Technology

Flavor Database: Through sufficient quality research and ingredients safety data collection, the composition, ingredient safety and characteristic spectrum of each flavor under a specific chromatographic system have been organized, and a flavor database covering dozens of flavors has been established, so as to provide sufficient methodological basis for flavor agent selection and analysis method development in the early stage of project research and development, reasonably controlling safety risks, and reducing research and development costs.

Physical masking: 1. Cyclodextrin and its derivatives, polymer micelles and vesicle technology are used to form complexes or inclusion complexes with API. 2. Masking coating the drug to achieve the isolation masking effect.

Chemical taste masking: Sweeteners, flavors or thickeners and other excipients are added to the formulation to achieve the effect of taste masking.

Taste Evaluation System

Electronic tongue evaluation system: In terms of taste evaluation system, our company has established an electronic tongue evaluation system and a human taste panel evaluation model (crossover blinding) to evaluate the palatability of the product from both subjective and objective perspectives to determine the optimal solution.

Core technology: The taste masking effect is evaluated by comparing the difference in the detection output signal of the drug after taste masking and the original bitter drug, supplemented by the scientific taste evaluation in clinical practice, verifying and correcting results of the device screening.

Evaluation effect: The use of electronic tongue to detect drugs can reduce the result bias caused by individual taste sensitivity differences and subjective perception differences, and the results are better reproducible.

Topical Dermatologic Technology

Sustained-Release Transdermal Spray Gel 

Global Innovative Dosage: Directional nebulized dosage form to achieve quantitative drug delivery to the skin.

Unique Sustained-Release Mechanism: The degradable polymer sustained-release skeleton structure is used to form a skin gel film after spraying, to achieve the slow release of active ingredients.

Clinical Advantages: Reducing the number of doses, easy to use, and improve patients' medication compliance.

Children friendly: Compared with conventional topical dermatologic cream or ointment, the gel is not easy to be washed off by water after application, improving pediatric medication compliance.

Innovative Compound Topical Gel

Global Innovative Compound Preparation: New compound with Quinolones antibacterial + Naphthoic acids anti-inflammatory agent.

Special Synergistic Mechanism: Quinolone antibacterials solely will easily induce resistance to Propionibacterium acnes, while naphthoic acid anti-inflammatory agents can effectively inhibit the resistance of Propionibacterium acnes and are expected to have a synergistic effect with quinolone antibacterials to enhance drug efficacy.

Technical barriers breakthrough: Selection of permeability enhancers, gelling agents and emulsifiers, micronization of active ingredients, gel stability, quality research of insoluble ingredients, etc.

Suitable for pediatric population: The active ingredients are listed in relevant domestic and international guidelines for young pediatric patients with high safety.

Patent Layout 

Independent intellectual property rights, covering new dosage form invention patents, with international and domestic layout.

Beimei Laboratory

  • 1
  • 1
  • 3
  • 4
  • 5
  • 6